ImmuPharma (IMML) Stock Overview
Engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IMML Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.037 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.037 |
| Beta | 3.02 |
| 1 Month Change | -15.45% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMML | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.9% |
| 1Y | n/a | 34.8% | 19.9% |
Return vs Industry: Insufficient data to determine how IMML performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IMML performed against the UK Market.
Price Volatility
| IMML volatility | |
|---|---|
| IMML Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: IMML's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine IMML's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology; and CDx, a companion diagnostic, which is in clinical trial for the identification of immune endotype and treatment of various autoimmune diseases. The company is also involved in the development of Kapiglucagon, a proprietary glucagon prodrug, which is in pre-clinical trial for the treatment of type 1 diabetes; BioAMB, an amphotericin-B therapy, which is in pre-clinical trial for the treatment of invasive fungal infections, such as aspergillosis; and BioCIN, a vancomycin-based therapy, which is in pre-clinical trial for the treatment of gram-positive infections comprising methicillin-resistant staphylococcus aureus, sepsis, lower respiratory tract infections, osteomyelitis, and skin infections.
ImmuPharma plc Fundamentals Summary
| IMML fundamental statistics | |
|---|---|
| Market cap | UK£23.37m |
| Earnings (TTM) | -UK£1.81m |
| Revenue (TTM) | n/a |
Is IMML overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMML income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£1.81m |
| Earnings | -UK£1.81m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0029 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMML perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 23:42 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuPharma plc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Glennie | Edison Investment Research |
| Paul Cuddon | Peel Hunt LLP |